Founder and Chief Executive Officer of ProQR. Daniel is a serial-entrepreneur and passionate advocate for rare disease patients. After one of his children was diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Under Daniel’s leadership ProQR developed a platform that yielded a diversified pipeline of potential treatments for rare diseases and raised over $300M in funding, including an IPO on Nasdaq. Before founding ProQR, Daniel was founder and Chief Executive Officer of several technology companies. Daniel is also co-founder and strategic advisor to Amylon Therapeutics and Wings Therapeutics, strategic advisor at Frame Therapeutics, Meatable, Algramo and a member of the board at the Termeer Foundation. In 2018 Daniel was named “Emerging Entrepreneur of the Year” by EY. In 2019 Daniel was selected for the Young Global Leader program at the World Economic Forum.